Amended Statement of Ownership (sc 13g/a)
February 11 2020 - 4:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
DENALI THERAPEUTICS INC.
(Name of Issuer)
Common Stock, Par Value $0.01 Per Share
(Title of Class of Securities)
24823R105
(CUSIP Number)
December 31, 2019
(Date of Event which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Douglas K. Bratton
United States
20,415,535 (1)
[ ]
21.3% (2)
IN
Crestline Investors, Inc.
Delaware
19,462,500 (1)
[ ]
20.3% (2)
CO
Crestline Management, L.P.
Delaware
19,462,500 (1)
[ ]
20.3% (2)
PN
Crestline SI (GP), L.P.
Delaware
19,462,500 (1)
[ ]
20.3% (2)
PN
AKDL, L.P.
Delaware
19,462,500
[ ]
20.3% (1)
PN
Bratton Capital, Inc.
Texas
953,035 (1)
[ ]
1.0% (2)
CO
Bratton Capital Management, L.P.
Texas
953,035 (1)
[ ]
1.0% (2)
PN
Neuro Line Partners, L.P.
Texas
953,035
[ ]
1.0% (1)
PN
AKDL, L.P. (“AKDL”), Crestline SI (GP), L.P. (“Crestline SI”), Crestline Management, L.P. (“Crestline Management”), Crestline Investors, Inc. (“Crestline”), Neuro Line Partners
L.P. (“Neuro Line”), Bratton Capital Management, L.P. (“Bratton Capital Management”), Bratton Capital, Inc. (“Bratton Capital”) and Douglas K. Bratton. Crestline SI is the general partner of AKDL and Crestline Management is the investment manager of
AKDL. Crestline is the general partner of Crestline SI and Crestline Management. Mr. Bratton is the sole director of Crestline. Bratton Capital Management is the general partner of Neuro Line. Bratton Capital is the general partner of Bratton
Capital Management. Mr. Bratton is the sole director of Bratton Capital.
Items 5 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference.
Each of the Reporting Persons expressly disclaims beneficial ownership of all shares of Common Stock reported herein other than those shares such Reporting Person holds
directly. The filing of this statement should not be construed to be an admission that the Reporting Persons are members of a “group” for the purposes of Section 13(d) and 13(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true,
complete and correct.
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Oct 2023 to Oct 2024